AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01558258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness practices (MAPs)
Description: Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
Study NCT03818074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Wavewriter 1000Hz Spinal cord Stimulation
Description: High frequency spinal cord stimulation.
Study NCT03442972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide
Study NCT03442972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03878602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Description: Umbilical cord will be clamped after 1 min after the birth of the newborn
Study NCT03522025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Arthroplasty (UKA)
Description: Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
Study NCT04544956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
Study NCT04544956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide therapy
Description: Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
Study NCT01801072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Details covered in Arm Descriptions.
Study NCT03878602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate umbilical cord clamping
Description: Umbilical cord will be clamped immediately after the birth of the newborn
Study NCT03886363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Described previously
Study NCT04791007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: vaginal or rectal administration
Study NCT02281864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention Bundle
Description: Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
Study NCT02281864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group: Quitline
Description: Referral to the Quitline
Study NCT02029612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Patch
Description: 10 week supply of nicotine patches given to participants at baseline.
Study NCT04199936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Muscle stimulation
Description: Electrical muscle stimulation
Study NCT03693170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: 300 mg administered orally once daily (QD)
Study NCT03693170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib 45 mg administered orally twice daily (BID)
Study NCT03693170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) :~(\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic.
Study NCT03130036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
Description: A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
Study NCT00311662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: Tablet 40mg daily for 12 weeks
Study NCT00311662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet once daily for 12 weeks
Study NCT04652232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RV3466F lotion
Description: Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application
Study NCT04652232 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shampoo
Description: Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application
Study NCT04652232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shampoo
Description: Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application
Study NCT04791007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: vaginal or rectal administration
Study NCT01406639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
Study NCT02494505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 2g/day per os
Study NCT02494505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01580046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodixanol
Description: 1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection
Study NCT01580046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iopromide
Description: coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
Study NCT00943865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet
Description: patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
Study NCT00943865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise recommendations
Description: Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
Study NCT00943865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pragmatic diet
Description: Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
Study NCT00943865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer-based fitness (10,000 steps)
Description: Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
Study NCT00943865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured assisted exercise (fitness)
Description: They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
Study NCT01995968 — intervention group
Intervention type: OTHER
Intervention: Antenatal identification of fetal growth restriction
Description: FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure
Study NCT01390948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
Study NCT01390948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
Study NCT01390948 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
Study NCT01390948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: 75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
Study NCT01390948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: 75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
Study NCT01588548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1208
Description: Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
Study NCT02029612 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phone Counseling
Description: Each participant counseled on quitting smoking at baseline.
Study NCT02029612 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 3 months, and at 6 months.
Study NCT02029612 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breath Test
Description: Breath test performed at 3 month and 6 month visit.
Study NCT02029612 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Proactive Cell Phone Smoking Cessation Counseling
Description: Participant receives 11 phone calls from study staff over a 6-month period.
Study NCT02029612 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Message Smoking Cessation Support
Description: Participants receive text messages for support about quitting smoking over a 6 month period.
Study NCT05102461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Florajen Digestion Supplementation
Description: Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
Study NCT05102461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
Study NCT03768973 — intervention group
Intervention type: PROCEDURE
Intervention: Elective cardiac surgery
Description: Both groups will undergo elective cardiac surgery as an intervention.
Study NCT00884377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium stibogluconate (Pentostam)
Description: intravenous 20 mg/kg/day for 10 days
Study NCT00884377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermoMed
Description: ThermoMed heat treatment device, one treatment
Study NCT02636335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips Energy Light HF3319
Description: Exposure to Light administered with Phillips Energy Light HF3319.
Study NCT01887340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: - carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)
Study NCT04435795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline intranasal and placebo inhaler
Description: Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
Study NCT04435795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Ciclesonide 600mcg BID inhaled with aero chamber
Study NCT04435795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal
Description: intranasal ciclesonide 200 mcg DIE
Study NCT01169805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron/single injection/4 mg/IV
Study NCT01169805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron HCl/single injection/0.3mg/IV
Study NCT01169805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron HCl/single injection/0.075mg/IV
Study NCT01887340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 D1 to D5
Study NCT01169805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline inj
Description: normal saline injection 2ml
Study NCT00913679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach (ReCap Hip Resurfacing System)
Description: two different surgical approaches in hip resurfacing arthroplasty
Study NCT01887340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg/m2 de D1 to D5
Study NCT04330183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.3mg/kg of ketamine
Study NCT04330183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 3cc of normal saline
Study NCT02413021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle
Study NCT02413021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle
Study NCT02413021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 20 mg/kg ,oral, per day
Study NCT04386967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: Oncolytic Type 2 Herpes Simplex Virus
Study NCT04386967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Anti-PD-1 antibody
Study NCT03564938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
Study NCT04041310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd-209-FSP low dose
Description: GAd20-209-FSP IP, low dose
Study NCT04041310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-209-FSP low dose
Description: MVA-209-FSP IP, low dose
Study NCT04041310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd-209-FSP high dose
Description: GAd20-209-FSP IP, high dose
Study NCT04041310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-209-FSP high dose
Description: MVA-209-FSP IP, high dose
Study NCT04041310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd20-209-FSP, RP2D
Description: GAd20-209-FSP IP, RP2D
Study NCT04041310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-209-FSP, RP2D
Description: MVA-209-FSP IP, RP2D
Study NCT04041310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
Study NCT04672460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALZENNA capsule
Description: Current commercial talazoparib formulation 1 mg once daily given under fasting condition
Study NCT04672460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib soft gel capsule
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
Study NCT04672460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib soft gel capsule
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
Study NCT04339218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly.
Study NCT04339218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
Study NCT02665650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFM13
Study NCT02665650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT01991106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Twelve weeks of 2-3 supervised training sessions each week.
Study NCT01991106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Description: Twelve weeks of 2-3 supervised training sessions each week.
Study NCT01991106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional advice
Description: healthy food choices, portion sizes and regular mealtimes
Study NCT01991106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional advice
Description: healthy food choices, portion sizes and regular mealtimes
Study NCT00742157 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Growth Hormone
Description: dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
Study NCT00834236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal subject
Description: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
Study NCT00834236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal subject
Description: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA